spacer gif spacer gif spacer gif spacer gif ARCHIVE ANNOUNCEMENT! spacer gif
QUICK SEARCH:   [advanced]


spacer gif
     Home     Help     Feedback     Subscriptions     Archive     Search     Table of Contents    

First published online 24 July 2008
doi: 10.1242/dev.020453

Development 135, 2959-2968 (2008)
Published by The Company of Biologists 2008
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Material
Right arrow All Versions of this Article:
dev.020453v1
135/17/2959    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Geske, M. J.
Right arrow Articles by Stappenbeck, T. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geske, M. J.
Right arrow Articles by Stappenbeck, T. S.

Fgf9 signaling regulates small intestinal elongation and mesenchymal development

Michael J. Geske1, Xiuqin Zhang2,*, Khushbu K. Patel1, David M. Ornitz2 and Thaddeus S. Stappenbeck1,{dagger}

1 Departments of Pathology and Immunology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA.
2 Department of Developmental Biology, Washington University School of Medicine, 660 South Euclid Avenue, St Louis, MO 63110, USA.

{dagger} Author for correspondence (e-mail: stappenb{at}pathology.wustl.edu)

Accepted 25 June 2008

Short bowel syndrome is an acquired condition in which the length of the small intestine is insufficient to perform its normal absorptive function. Current therapies are limited as the developmental mechanisms that normally regulate elongation of the small intestine are poorly understood. Here, we identify Fgf9 as an important epithelial-to-mesenchymal signal required for proper small intestinal morphogenesis. Mouse embryos that lack either Fgf9 or the mesenchymal receptors for Fgf9 contained a disproportionately shortened small intestine, decreased mesenchymal proliferation, premature differentiation of fibroblasts into myofibroblasts and significantly elevated Tgfβ signaling. These findings suggest that Fgf9 normally functions to repress Tgfβ signaling in these cells. In vivo, a small subset of mesenchymal cells expressed phospho-Erk and the secreted Tgfβ inhibitors Fst and Fstl1 in an Fgf9-dependent fashion. The p-Erk/Fst/Fstl1-expressing cells were most consistent with intestinal mesenchymal stem cells (iMSCs). We found that isolated iMSCs expressed p-Erk, Fst and Fstl1, and could repress the differentiation of intestinal myofibroblasts in co-culture. These data suggest a model in which epithelial-derived Fgf9 stimulates iMSCs that in turn regulate underlying mesenchymal fibroblast proliferation and differentiation at least in part through inhibition of Tgfβ signaling in the mesenchyme. Taken together, the interaction of FGF and TGFβ signaling pathways in the intestinal mesenchyme could represent novel targets for future short bowel syndrome therapies.

Key words: Fibroblast growth factor 9 (Fgf9), Gut development, Tgfβ signaling, Epithelial-mesenchymal crosstalk, Mesenchymal stem cells, Follistatin, Mouse






© The Company of Biologists Ltd 2008